/INBS
INBS Stock - Intelligent Bio Solutions Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$6.14-12.16%
$0.85 (-12.16%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $6.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INBS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.08 – $6.20
TARGET (TP)$7.06
STOP LOSS$5.65
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.51
52W High$27.50
52W Low$5.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.05M | $3.11M | $1.26M | N/A | $1.98M |
| Gross Profit | $1.25M | $1.43M | $326,668 | N/A | $1.98M |
| Gross Margin | 40.8% | 45.8% | 26.0% | N/A | 100.0% |
| Operating Income | $-10,644,607 | $-10,283,174 | $-12,595,233 | $-8,336,876 | $-5,573,482 |
| Net Income | $-10,568,733 | $-10,156,759 | $-10,631,720 | $-8,306,051 | $-7,037,286 |
| Net Margin | -346.2% | -326.4% | -845.9% | N/A | -355.3% |
| EPS | $-20.00 | $-63.80 | $-105.80 | $-113.30 | $-162.20 |
Company Overview
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INBSBeat Rate
47%
Last 15 quarters
Avg Surprise
-77.5%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-3.50
Q4 2025
EPS Surprise History
Q1 24
+36.1%
$-2.07vs$-3.24
Q2 24
-64.4%
$-1.43vs$-0.87
Q3 24
-162.7%
$-1.34vs$-0.51
Q4 24
-32.1%
$-0.70vs$-0.53
Q1 25
+84.4%
$-0.50vs$-3.20
Q2 25
+84.3%
$-0.44vs$-2.80
Q3 25
+69.2%
$-0.37vs$-1.20
Q4 25
-133.3%
$-3.50vs$-1.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.50 | $-3.50 | -133.3% | ✗ MISS |
Q3 2025 | Aug 15, 2025 | $-1.20 | $-0.37 | +69.2% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-2.80 | $-0.44 | +84.3% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-3.20 | $-0.50 | +84.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.53 | $-0.70 | -32.1% | ✗ MISS |
Q3 2024 | Sep 19, 2024 | $-0.51 | $-1.34 | -162.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.87 | $-1.43 | -64.4% | ✗ MISS |
Q1 2024 | Feb 9, 2024 | $-3.24 | $-2.07 | +36.1% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-7.68 | $-12.48 | -62.5% | ✗ MISS |
Q3 2023 | Aug 24, 2023 | $-19.93 | $-22.93 | -15.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-2.07 | $-24.37 | -1077.3% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-2.20 | $-0.46 | +79.1% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | — | $-55.57 | — | — |
Q4 2022 | Nov 9, 2022 | $-24.00 | $-16.23 | +32.4% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-3.20 | $-1.80 | +43.8% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $-3.20 | $-4.60 | -43.7% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-20.46 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-12.56 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-53.03 | — | — |
Latest News
Intelligent Bio Solutions Partners With Vlepis To Tap Consumer Health Monitoring Market
📈 PositiveBenzinga•Dec 18, 2025, 01:35 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 16, 2025, 12:50 AM
Intelligent Bio Solutions shares are trading lower after the company announced a 1-For-10 reverse split.
📉 NegativeBenzinga•Dec 12, 2025, 06:12 PM
Intelligent Bio Solutions Announces 1-For-10 Reverse Split, Effective December 15
📉 NegativeBenzinga•Dec 12, 2025, 03:33 PM
Intelligent Bio Solutions Q1 EPS $(0.35) Up From $(0.70) YoY, Sales $1.112M Up From $872.287K YoY
📈 PositiveBenzinga•Nov 12, 2025, 01:37 PM
Intelligent Bio Solutions Expects To Report Q1 Revenue Growth Of ~32% Sequentially And 28% YoY
📈 PositiveBenzinga•Nov 4, 2025, 01:32 PM
Intelligent Bio Solutions Announces Addition Of 33 New Customer Accounts During Q1
📈 PositiveBenzinga•Oct 30, 2025, 12:35 PM
Intelligent Bio Solutions shares are trading higher after the company announced a UK contract with an industrial service provider.
📈 PositiveBenzinga•Oct 23, 2025, 12:33 PM
Intelligent Bio Solutions Secures UK Contract With An Industrial Service Provider, Size Not Disclosed
📈 PositiveBenzinga•Oct 23, 2025, 12:32 PM
Intelligent Bio Solutions Initiates Clinical Studies For Fingerprint Drug Screening System; Targets FDA 510(k) Clearance In H2 2026 For Codeine Detection
📈 PositiveBenzinga•Sep 26, 2025, 12:37 PM
Intelligent Bio Solutions shares are trading lower after the company announced it received FDA feedback and is preparing to resubmit 510(k) for its Intelligent Fingerprinting Drug Screening System.
➖ NeutralBenzinga•Sep 17, 2025, 01:14 PM
Intelligent Bio Solutions Receives FDA Feedback, Preparing To Resubmit 510(k) For Intelligent Fingerprinting Drug Screening System
➖ NeutralBenzinga•Sep 17, 2025, 12:34 PM
Intelligent Bio Solutions Posts 60% YoY Growth In July Cartridge Sales, Surpassing 12,500 Units
📈 PositiveBenzinga•Aug 19, 2025, 01:07 PM
Frequently Asked Questions about INBS
What is INBS's current stock price?
Intelligent Bio Solutions Inc. (INBS) is currently trading at $6.14 per share. The stock has moved -12.16% today.
What is the analyst price target for INBS?
No analyst price targets are currently available for this stock.
What sector is Intelligent Bio Solutions Inc. in?
Intelligent Bio Solutions Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is INBS's market cap?
Intelligent Bio Solutions Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does INBS pay dividends?
No, Intelligent Bio Solutions Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
BNGO
Bionano Genomics, Inc.
$1.60
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
HSCS
HeartSciences Inc.
$2.36
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
MYNZ
Mainz Biomed B.V.
$1.20
Mkt Cap: $0.0B
PAVM
PAVmed Inc.
$0.31
Mkt Cap: $0.0B
POAI
Predictive Oncology Inc.
$5.95
Mkt Cap: $0.0B
SSKN
STRATA Skin Sciences, Inc.
$1.19
Mkt Cap: $0.0B
Explore stocks similar to INBS for comparison